|
1 Indications And Usage Steglujan™ Is Indicated As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus When Treatment With Both Ertugliflozin And Sitagliptin Is Appropriate. Steglujan Is A Combination Of Ertugliflozin, A Sodium Glucose Co-Transporter 2 (Sglt2) Inhibitor, And Sitagliptin, A Dipeptidyl Peptidase-4 (Dpp-4) Inhibitor, Indicated As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus When Treatment With Both Ertugliflozin And Sitagliptin Is Appropriate. ( 1 ) Limitations Of Use: Not For The Treatment Of Type 1 Diabetes Mellitus Or Diabetic Ketoacidosis. ( 1 ) Has Not Been Studied In Patients With A History Of Pancreatitis. ( 1 , 5.1 ) Limitations Of Use Steglujan Is Not Recommended In Patients With Type 1 Diabetes Mellitus Or For The Treatment Of Diabetic Ketoacidosis. Steglujan Has Not Been Studied In Patients With A History Of Pancreatitis. It Is Unknown Whether Patients With A History Of Pancreatitis Are At Increased Risk For The Development Of Pancreatitis While Using Steglujan. [See Warnings And Precautions (5.1) .]
|